Literature DB >> 12534369

High glucose and insulin in combination cause insulin receptor substrate-1 and -2 depletion and protein kinase B desensitisation in primary cultured rat adipocytes: possible implications for insulin resistance in type 2 diabetes.

Jonas Burén1, Hui-Xia Liu, Johan Lauritz, Jan W Eriksson.   

Abstract

OBJECTIVE: The purpose of this study was to investigate the cellular effects of long-term exposure to high insulin and glucose levels on glucose transport and insulin signalling proteins. DESIGN AND METHODS: Rat adipocytes were cultured for 24 h in different glucose concentrations with 10(4) microU/ml of insulin or without insulin. After washing, (125)I-insulin binding, basal and acutely insulin-stimulated d-[(14)C]glucose uptake, and insulin signalling proteins and glucose transporter 4 (GLUT4) were assessed.
RESULTS: High glucose (15 and 25 mmol/l) for 24 h induced a decrease in basal and insulin-stimulated glucose uptake compared with control cells incubated in low glucose (5 or 10 mmol/l). Twenty-four hours of insulin treatment decreased insulin binding capacity by approximately 40%, and shifted the dose-response curve for insulin's acute effect on glucose uptake 2- to 3-fold to the right. Twenty-four hours of insulin treatment reduced basal and insulin-stimulated glucose uptake only in the presence of high glucose (by approximately 30-50%). At high glucose, insulin receptor substrate-1 (IRS-1) expression was downregulated by approximately 20-50%, whereas IRS-2 was strongly upregulated by glucose levels of 10 mmol/l or more (by 100-400%). Insulin treatment amplified the suppression of IRS-1 when combined with high glucose and also IRS-2 expression was almost abolished. Twenty-four hours of treatment with high glucose or insulin, alone or in combination, shifted the dose-response curve for insulin's effect to acutely phosphorylate protein kinase B (PKB) to the right. Fifteen mmol/l glucose increased GLUT4 in cellular membranes (by approximately 140%) compared with 5 mmol/l but this was prevented by a high insulin concentration.
CONCLUSIONS: Long-term exposure to high glucose per se decreases IRS-1 but increases IRS-2 content in rat adipocytes and it impairs glucose transport capacity. Treatment with high insulin downregulates insulin binding capacity and, when combined with high glucose, it produces a marked depletion of IRS-1 and -2 content together with an impaired sensitivity to insulin stimulation of PKB activity. These mechanisms may potentially contribute to insulin resistance in type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12534369     DOI: 10.1530/eje.0.1480157

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  25 in total

1.  Tissue kallikrein reverses insulin resistance and attenuates nephropathy in diabetic rats by activation of phosphatidylinositol 3-kinase/protein kinase B and adenosine 5'-monophosphate-activated protein kinase signaling pathways.

Authors:  Gang Yuan; Juanjuan Deng; Tao Wang; Chunxia Zhao; Xizheng Xu; Peihua Wang; James W Voltz; Matthew L Edin; Xiao Xiao; Lee Chao; Julie Chao; Xin A Zhang; Darryl C Zeldin; Dao Wen Wang
Journal:  Endocrinology       Date:  2007-02-01       Impact factor: 4.736

2.  Insulin-like growth factor-I-stimulated insulin receptor substrate-1 negatively regulates Src homology 2 domain-containing protein-tyrosine phosphatase substrate-1 function in vascular smooth muscle cells.

Authors:  Yashwanth Radhakrishnan; Walker H Busby; Xinchun Shen; Laura A Maile; David R Clemmons
Journal:  J Biol Chem       Date:  2010-03-05       Impact factor: 5.157

3.  Glycogen synthase kinase 3 beta mediates high glucose-induced ubiquitination and proteasome degradation of insulin receptor substrate 1.

Authors:  Sanhua Leng; Wenshuo Zhang; Yanbin Zheng; Ziva Liberman; Christopher J Rhodes; Hagit Eldar-Finkelman; Xiao Jian Sun
Journal:  J Endocrinol       Date:  2010-05-13       Impact factor: 4.286

4.  Effect of glucocorticoid-induced insulin resistance on follicle development and ovulation.

Authors:  Katherine S Hackbart; Pauline M Cunha; Rudelle K Meyer; Milo C Wiltbank
Journal:  Biol Reprod       Date:  2013-06-20       Impact factor: 4.285

5.  Topical insulin accelerates cutaneous wound healing in insulin-resistant diabetic rats.

Authors:  Tianyi Yu; Min Gao; Peilang Yang; Qing Pei; Dan Liu; Di Wang; Xiong Zhang; Yan Liu
Journal:  Am J Transl Res       Date:  2017-10-15       Impact factor: 4.060

6.  Combined Hyperglycemia- and Hyperinsulinemia-Induced Insulin Resistance in Adipocytes Is Associated With Dual Signaling Defects Mediated by PKC-ζ.

Authors:  Huogen Lu; Elena Bogdanovic; Zhiwen Yu; Charles Cho; Lijiang Liu; Karen Ho; June Guo; Lucy S N Yeung; Reiner Lehmann; Harinder S Hundal; Adria Giacca; I George Fantus
Journal:  Endocrinology       Date:  2018-04-01       Impact factor: 4.736

Review 7.  Modulation of insulin action.

Authors:  L Pirola; A M Johnston; E Van Obberghen
Journal:  Diabetologia       Date:  2004-01-13       Impact factor: 10.122

8.  Resistin disrupts glycogen synthesis under high insulin and high glucose levels by down-regulating the hepatic levels of GSK3β.

Authors:  Rongjing Song; Xi Wang; Yiqing Mao; Hui Li; Zhixin Li; Wei Xu; Rong Wang; Tingting Guo; Ling Jin; Xiaojing Zhang; Yizhuang Zhang; Na Zhou; Ruobi Hu; Jianwei Jia; Zhen Lei; David M Irwin; Gang Niu; Huanran Tan
Journal:  Gene       Date:  2013-07-13       Impact factor: 3.688

9.  Insulin-like growth factor-I stimulates Shc-dependent phosphatidylinositol 3-kinase activation via Grb2-associated p85 in vascular smooth muscle cells.

Authors:  Yashwanth Radhakrishnan; Laura A Maile; Yan Ling; Lee M Graves; David R Clemmons
Journal:  J Biol Chem       Date:  2008-04-16       Impact factor: 5.157

10.  Intact glucose uptake despite deteriorating signaling in adipocytes with high-fat feeding.

Authors:  Björn Hansson; Sebastian Wasserstrom; Björn Morén; Vipul Periwal; Petter Vikman; Samuel W Cushman; Olga Göransson; Petter Storm; Karin G Stenkula
Journal:  J Mol Endocrinol       Date:  2018-01-16       Impact factor: 5.098

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.